Analytical Data
-
基因名
SFTPA2
- Application
-
别名
PSP-A;PSPA;SP-A;SP-A2;35 kDa pulmonary surfactant-associated Protein;Alveolar Proteinosis Protein;Collectin-5
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8IWL1
-
表达区间
1-248 aa
-
氨基酸序列
MWLCPLALNLILMAASGAACEVKDVCVGSPGIPGTPGSHGLPGRDGRDGVKGDPGPPDPMGPPGETPCPPGNNGLPGAPGVPGERGEKGEAGERGPPGLPAHLDEELQATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKKYNTYAYVGLTEGPSPGDFRYSDGTPVNYTNWYRGEPAGRGKEQCVEMYTDGQWNDRNCLYSRLTICDF
-
分子量
53.68 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SFTPA2, or surfactant protein A2, is a vital component of the pulmonary surfactant system, playing a crucial role in maintaining alveolar stability and host defense in the lungs. As part of the collectin family of proteins, SFTPA2 is involved in the recognition and clearance of pathogens, as well as modulating immune responses within the respiratory system. Abnormalities in SFTPA2 expression and function have been linked to various lung diseases, including acute respiratory distress syndrome (ARDS), pneumonia, and surfactant dysfunction disorders. Consequently, the study of recombinant SFTPA2 protein holds significant promise for understanding these diseases and developing therapeutic interventions. Recent advancements in recombinant DNA technology have enabled the production of SFTPA2 in heterologous systems, facilitating detailed biochemical and biophysical characterization. This research not only elucidates the protein's structure-function relationships but also explores its potential as a biomarker for lung disease and a target for pharmacological interventions. As scientists continue to investigate the mechanisms underlying surfactant protein dysfunction, the insights gained from SFTPA2 recombinant protein studies may lead to novel strategies for improving lung health and combating respiratory diseases.
